ArticleFrontiers in oncology2025
The effect of interval time of transcatheter arterial chemoembolization with drug-eluting beads on the efficacy and safety of unresectable hepatocellular carcinoma: a case-control study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the effect of treatment interval on the efficacy and safety of transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE) in patients with unresectable hepatocellular carcinoma (HCC). Methods: Retrospective analysis of clinical data of HCC patients admitted to our hospital from December 2015 to December 2023. Kaplan Meier method was used to calculate survival rate, survival curve was plotted, log rank test was used for univariate analysis, and Cox regression model was used to analyze independent prognostic factors. Select cutoff values based on OS using X-tile software for grouping, and compare the impact of time intervals on OS and adverse reactions. Results: The median OS of the entire group was 26 months, and the 1-, 3-, and 5-year survival rates were 85.6%, 48.3%, and 41.8%, respectively. Multi factor analysis shows that, BCLC, The occurrence of splenomegaly, targeted therapy, and TACE interval are independent prognostic factors for overall survival. The analysis of treatment interval grouping showed that the cut-off value of TACE time interval was 4 weeks. The group with TACE interval>4 weeks (long interval group) showed better survival benefits than the group with TACE interval<4 weeks (short interval group) (mOS: 47 Conclusion: DEB-TACE performed at intervals longer than 4 weeks has a better prognosis for HCC than DEB-TACE performed within 4 weeks without increasing adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.